Medical diagnostic equipment manufacturer GE Healthcare has launched Serena Bright, a contrast-enhanced mammography solution for biopsy.

Claimed to be the industry’s first contrast-enhanced mammography solution for biopsy, the device is yet to receive FDA 510k approval in the US.

GE Healthcare women’s health president & CEO Agnes Berzsenyi said: “We are thrilled to introduce this industry-first solution to equip clinicians with another key tool in the fight against breast cancer. Through a multi-modality and personalized approach, our hope is that we can find cancers earlier to ultimately improve outcomes and save lives.”

Serena Bright, CESM biopsy would improve diagnostic confidence in radiologists

Interventional and biopsy procedures are required in most diagnoses of breast cancer. Although contrast-enhanced biopsies are performed with breast MR for lesions that cannot be seen on mammography or ultrasound, the process can be more time-consuming, uncomfortable and costly for patients.

The Serena Bright facilitates breast biopsy exams to be performed with the same mammography equipment and in the same room as the screening or diagnostic mammogram. The device is claimed to save time, lower costs and improve the patient experience.

GE Healthcare said that its SenoBright HD Contrast Enhanced Spectral Mammography (CESM) is a diagnostic imaging tool designed to detect malignant lesions.

CESM biopsy, along with Serena Bright, highlights the areas of unusual blood flow to help localise the lesions needed to be biopsied, and this improves radiologists’ diagnostic confidence.

Institut Gustave Roussy medical imaging head Corinne Balleyguier said: “This new mammography-guided biopsy technique offers an alternative to MR-guided breast biopsy, which can improve the patient experience and allow us to get answers to patients faster.

“We are proud to be the first in the world to be able to offer this technology to our patients and believe this will have a significant impact on breast imaging capabilities.”